I

Innate Pharma SA
D

IPHA

1.84000
USD
-0.03
(-1.60%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
169,570,348
أصول ذات صلة
A
ADMA
0.120
(0.66%)
18.260 USD
A
AKBA
-0.00500
(-0.14%)
3.61500 USD
A
ARDX
0.08000
(1.90%)
4.28000 USD
B
BCRX
-0.10000
(-1.11%)
8.94000 USD
F
FGEN
0.40000
(7.59%)
5.67000 USD
INSM
INSM
-0.476
(-0.48%)
97.760 USD
K
KPTI
-0.21000
(-4.57%)
4.39000 USD
M
MDGL
-2.26
(-0.75%)
298.20 USD
X
XNCR
0.09500
(1.14%)
8.40000 USD
المزيد
الأخبار المقالات

العنوان: Innate Pharma SA

القطاع: Healthcare
الصناعة: Biotechnology
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.